RYALTRIS 25 micrograms/600 micrograms/dose, suspension for spraying nasal bottle, 30 ml
Active ingredients: Olopatadine hydrochloride, Mometasone furoate, Mometasone furoate monohydrate, OLOPATADINE
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for sprayingbottle, 30 mlnasale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RYALTRIS 25 microgrammes/600 microgrammes/dose, suspension pour pulvérisation nasale
- Pharmaceutical form
- suspension pour pulvérisation
- Route of administration
- nasale
- Presentation description
- 1 flacon polyéthylène haute densité (PEHD) de 30 mL avec pompe doseuse (240 pulvérisations)
- Marketing authorisation holder
- GLENMARK PHARMACEUTICALS (REPUBLIQUE TCHEQUE)
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Mar 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64475839CIP73024059CIP133400930240595Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUROATE DE MOMÉTASONEsuspension | 25 microgrammes · une dose délivrée | FT |
| CHLORHYDRATE D'OLOPATADINEsuspension | — | SA |
| FUROATE DE MOMÉTASONE MONOHYDRATÉsuspension | — | SA |
| OLOPATADINEsuspension | 600 microgrammes · une dose délivrée | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.